Want to make the most of ASGCT 2026? Start here.
Booth #1549 | Boston, MA | May 13-15, 2026
Viralgen has everything you need to maximize your AAV gene therapy manufacturing opportunities.
It starts with an unmatched track record — including 30+ serotypes, over 1,500 AAV runs, and a 100% IND/IMPD dossier submission success rate.
We put all that experience into action with Aava™, the high-performance manufacturing platform that delivers better predictability, superior speed, and deeper data. Even better, you can choose Aava Mendi—built for speed and stability—or Aava Iturri—made for scale and efficiency—to get the best match for your strategic goals.
Let’s meet up in Boston. And see just how far your gene therapy can go from there.
Schedule A Meeting
Meet
The first choice in AAV gene therapy manufacturing now has a first name. Learn more about the most proven platform in the industry, available only from Viralgen.
Fresh research on AAV manufacturing
Stop by Poster Hall 12 throughout the week for a quintet of research updates from the scientific and technology leads at Viralgen who are helping shape the future of AAV-based gene therapy manufacturing.
Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen
Presented by Cesar Trigueros
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA988
Benefits of High-Throughput Sequencing-Based Methods for In-Depth Characterization of Recombinant AAV Products
Presented by Sonia Stinus
May 14, 5:30-7pm CT
Poster Hall I2
Poster # AMA905
Enhancing the Upstream Performance of Adeno-Associated Virus (AAV) Vector Manufacturing via Multivariate Data Analysis
Presented by Ainara Apezteguia
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1624
Leveraging Historical Data and Percentile based Modeling for Improved AAV Production Scaling
Presented by Itsasne Arangoa
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1546
Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing
Presented by Itsasne Arangoa
May 13, 6-7:30pm CT
Poster Hall I2
Poster # AMA1539
Let’s Connect
Bayer fully supports coordinated vulnerability disclosure and encourages security researchers who choose to engage in these actions to do so in a responsible manner.
Coordinated Vulnerability Disclosure Statement
